Roberts Meredith A, Tran Dominic, Coulombe Kareen L K, Razumova Maria, Regnier Michael, Murry Charles E, Zheng Ying
1 Department of Bioengineering, University of Washington , Seattle, Washington.
2 Center for Cardiovascular Biology, University of Washington , Seattle, Washington.
Tissue Eng Part A. 2016 Apr;22(7-8):633-44. doi: 10.1089/ten.TEA.2015.0482. Epub 2016 Mar 31.
Cardiac tissue engineering is a strategy to replace damaged contractile tissue and model cardiac diseases to discover therapies. Current cardiac and vascular engineering approaches independently create aligned contractile tissue or perfusable vasculature, but a combined vascularized cardiac tissue remains to be achieved. Here, we sought to incorporate a patterned microvasculature into engineered heart tissue, which balances the competing demands from cardiomyocytes to contract the matrix versus the vascular lumens that need structural support. Low-density collagen hydrogels (1.25 mg/mL) permit human embryonic stem cell-derived cardiomyocytes (hESC-CMs) to form a dense contractile tissue but cannot support a patterned microvasculature. Conversely, high collagen concentrations (density ≥6 mg/mL) support a patterned microvasculature, but the hESC-CMs lack cell-cell contact, limiting their electrical communication, structural maturation, and tissue-level contractile function. When cocultured with matrix remodeling stromal cells, however, hESC-CMs structurally mature and form anisotropic constructs in high-density collagen. Remodeling requires the stromal cells to be in proximity with hESC-CMs. In addition, cocultured cardiac constructs in dense collagen generate measurable active contractions (on the order of 0.1 mN/mm(2)) and can be paced up to 2 Hz. Patterned microvascular networks in these high-density cocultured cardiac constructs remain patent through 2 weeks of culture, and hESC-CMs show electrical synchronization. The ability to maintain microstructural control within engineered heart tissue enables generation of more complex features, such as cellular alignment and a vasculature. Successful incorporation of these features paves the way for the use of large scale engineered tissues for myocardial regeneration and cardiac disease modeling.
心脏组织工程是一种替代受损收缩组织并模拟心脏疾病以发现治疗方法的策略。目前的心脏和血管工程方法分别创建排列整齐的收缩组织或可灌注的脉管系统,但尚未实现血管化心脏组织的联合构建。在此,我们试图将有图案的微血管整合到工程化心脏组织中,这需要平衡心肌细胞收缩基质的需求与需要结构支撑的血管腔之间的竞争需求。低密度胶原蛋白水凝胶(1.25毫克/毫升)能使人胚胎干细胞衍生的心肌细胞(hESC-CMs)形成致密的收缩组织,但无法支撑有图案的微血管。相反,高胶原蛋白浓度(密度≥6毫克/毫升)能支撑有图案的微血管,但hESC-CMs缺乏细胞间接触,限制了它们的电通讯、结构成熟和组织水平的收缩功能。然而,当与基质重塑基质细胞共培养时,hESC-CMs在高密度胶原蛋白中结构成熟并形成各向异性构建体。重塑要求基质细胞与hESC-CMs相邻。此外,在致密胶原蛋白中共培养的心脏构建体产生可测量的主动收缩(约0.1毫牛/平方毫米),并且可以以高达2赫兹的频率起搏。这些高密度共培养心脏构建体中的有图案微血管网络在培养2周后仍保持通畅,并且hESC-CMs表现出电同步。在工程化心脏组织内维持微观结构控制的能力能够产生更复杂的特征,如细胞排列和脉管系统。成功整合这些特征为使用大规模工程组织进行心肌再生和心脏疾病建模铺平了道路。